EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Porcine Reproductive and Respiratory Syndrome Virus: Challenges and Advances in Vaccine Development

Zhan He, Fangfang Li, Min Liu, Jiali Liao, Chunhe Guo iD

Vaccines · 28.02.2025 · 13 (3) · 260

DOI: 10.3390/vaccines13030260 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 28.02.2025. Verfasst von Zhan He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Laboratory for Lingnan Modern Agriculture, State Key Laboratory for Animal Disease Control and Prevention, Key Laboratory of Zoonosis Preve…. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China, the Basic and Applied Basic Research Foundation of Guangdong Province, the Science and Technology Planning Project of Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent infection of porcine reproductive and respiratory syndrome virus (PRRSV) significantly hampers both the quantity and quality of pork production in China. Although PRRSV is widely prevalent worldwide, the absence of effective vaccines has made it one of the major pathogens threatening the sustainable development of the global swine industry. Vaccination remains one of the most effective measures for controlling pathogen infections. However, the continuous genetic recombination and mutation of PRRSV demand more comprehensive strategies to address emerging threats, while ensuring the efficacy and safety of vaccines. This review provides an overview of the latest advances in PRRSV vaccine research, highlighting the importance of understanding the unique strengths and limitations of various vaccines in developing effective therapeutic approaches and vaccination strategies. Moreover, the development of adjuvants and antiviral drugs as adjuncts to combat PRRSV infection offers significant potential for enhancing disease control efforts. With the advancement of technologies such as proteolysis-targeting chimera (PROTAC) and mRNA, new avenues for controlling PRRSV and other pathogens are emerging, offering considerable hope. Ultimately, the goal of these vaccine developments is to alleviate the impact of PRRSV on animal health and the profitability of the swine industry.

Schlagwörter

Stichwörter der Autor:innen

PRRSVimmunogenicityprotection effectvaccine

Autor:innen und Institutionen

  • Guangdong Laboratory for Lingnan Modern Agriculture, State Key Laboratory for Animal Disease Control and Prevention, Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, College of Veterinary Medicin…

ORCID-Profile: Chunhe Guo

Förderung

  • the National Key Research and Development Program of China
  • the Basic and Applied Basic Research Foundation of Guangdong Province
  • the Science and Technology Planning Project of Guangzhou
  • SCAU & Wens Science and Technology Innovation Center Project
  • National Key Research and Development Program of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Science and Technology Planning Project of Guangzhou
  • SCAU & Wens Science and Technology Innovation Center Project

Zitieren

APA

He, Z., Li, F., Liu, M., Liao, J., & Guo, C. (2025). Porcine Reproductive and Respiratory Syndrome Virus: Challenges and Advances in Vaccine Development. Vaccines, 13(3), 260. https://doi.org/10.3390/vaccines13030260

Vancouver

He Z, Li F, Liu M, Liao J, Guo C. Porcine Reproductive and Respiratory Syndrome Virus: Challenges and Advances in Vaccine Development. Vaccines. 2025;13(3):260. doi:10.3390/vaccines13030260

BibTeX
@article{He2025,
  author = {He, Zhan and Li, Fangfang and Liu, Min and Liao, Jiali and Guo, Chunhe},
  title = {Porcine Reproductive and Respiratory Syndrome Virus: Challenges and Advances in Vaccine Development},
  journal = {Vaccines},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {260},
  doi = {10.3390/vaccines13030260}
}
Kostenlos starten →